{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002868","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.988128+00:00","generated_at":"2026-05-28T03:44:53.618684+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MindMed terminates Executive President Miri Halperin Wernli without cause, effective Feb 28, 2025","bullets":["Employment terminated without cause; effective February 28, 2025.","Reason cited: centralizing management team in the United States for strategic alignment.","No replacement announced; CEO Robert Barrow remains.","Updated corporate presentation filed as Exhibit 99.1 on January 13, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002868","json":"https://secwatch.observer/filing/0001104659-25-002868.json","markdown":"https://secwatch.observer/filing/0001104659-25-002868.md","text":"https://secwatch.observer/filing/0001104659-25-002868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000110465925002868/0001104659-25-002868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000110465925002868/tm253011d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:44:53.618684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f67e6f244","claim":"Miri Halperin Wernli was terminated as Executive President at Definium Therapeutics, Inc..","evidence_excerpt":"On January 10, 2025, Mind Medicine (MindMed) Inc. (the \"Company\") notified Miri Halperin Wernli, the Company's Executive President, that it was terminating her employment without cause, effective February 28, 2025, as the Company centralizes its management team in the United States to enhance collaboration and alignment with its strategic goals.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000110465925002868/0001104659-25-002868-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Executive President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}